207 related articles for article (PubMed ID: 38380327)
61. Response to treatment with an ALK-TKI in a patient with advanced lung adenocarcinoma with concurrent ALK fusion and high PD-L1 expression: A case report.
Zhang Y; Fang H; Hong J; Wang X; Wang H; Pan G
Medicine (Baltimore); 2022 Aug; 101(33):e30094. PubMed ID: 35984185
[TBL] [Abstract][Full Text] [Related]
62. ALK Inhibitor Treatment Patterns and Outcomes in Real-World Patients with ALK-Positive Non-Small-Cell Lung Cancer: A Retrospective Cohort Study.
Wang M; Slatter S; Sussell J; Lin CW; Ogale S; Datta D; Butte AJ; Bazhenova L; Rudrapatna VA
Target Oncol; 2023 Jul; 18(4):571-583. PubMed ID: 37341856
[TBL] [Abstract][Full Text] [Related]
63. A novel alectinib-sensitive CTNND1-ALK fusion in a lung adenocarcinoma patient: a case report.
Tian X; Liao Q; Yang Q; Chen L; Xiao M; Cheng Y
Invest New Drugs; 2022 Aug; 40(4):850-853. PubMed ID: 35441911
[TBL] [Abstract][Full Text] [Related]
64. [A Case of Advanced Lung Squamous Cell Carcinoma with CLIP1-ALK Fusion Gene].
Yuan Y; Wang Z; Nie X; Zhang P; Li L
Zhongguo Fei Ai Za Zhi; 2022 Sep; 25(9):696-700. PubMed ID: 36172736
[TBL] [Abstract][Full Text] [Related]
65. ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib.
Kim ES; Barlesi F; Mok T; Ahn MJ; Shen J; Zhang P; Ou SI
Future Oncol; 2021 May; 17(14):1709-1719. PubMed ID: 33569983
[TBL] [Abstract][Full Text] [Related]
66. Expert consensus of management of adverse drug reactions with anaplastic lymphoma kinase tyrosine kinase inhibitors.
Zhou F; Yang Y; Zhang L; Cheng Y; Han B; Lu Y; Wang C; Wang Z; Yang N; Fan Y; Wang L; Ma Z; Zhang L; Yao Y; Zhao J; Dong X; Zhu B; Zhou C
ESMO Open; 2023 Jun; 8(3):101560. PubMed ID: 37230029
[TBL] [Abstract][Full Text] [Related]
67. [Whole-process Management of Treatment of Advanced ALK Positive Non-small Cell Lung Cancer: A Case Report].
Bai H; Han Y; Niu Y; Zhang M
Zhongguo Fei Ai Za Zhi; 2021 Aug; 24(8):598-604. PubMed ID: 34344501
[TBL] [Abstract][Full Text] [Related]
68. Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer.
Karachaliou N; Santarpia M; Gonzalez Cao M; Teixido C; Sosa AE; Berenguer J; Rodriguez Capote A; Altavilla G; Rosell R
Expert Opin Investig Drugs; 2017 Jun; 26(6):713-722. PubMed ID: 28463570
[TBL] [Abstract][Full Text] [Related]
69. Co-alteration of EGFR mutation and ALK rearrangement in non-small cell lung cancer: Case series.
Shin HJ; Kho BG; Kim MS; Park HY; Kim TO; Kim YI; Lim SC; Park CK; Kim YC; Choi YD; Oh IJ
Medicine (Baltimore); 2019 Mar; 98(9):e14699. PubMed ID: 30817606
[TBL] [Abstract][Full Text] [Related]
70. Management and future directions in non-small cell lung cancer with known activating mutations.
Gerber DE; Gandhi L; Costa DB
Am Soc Clin Oncol Educ Book; 2014; ():e353-65. PubMed ID: 24857124
[TBL] [Abstract][Full Text] [Related]
71. Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer.
Lin JJ; Zhu VW; Yoda S; Yeap BY; Schrock AB; Dagogo-Jack I; Jessop NA; Jiang GY; Le LP; Gowen K; Stephens PJ; Ross JS; Ali SM; Miller VA; Johnson ML; Lovly CM; Hata AN; Gainor JF; Iafrate AJ; Shaw AT; Ou SI
J Clin Oncol; 2018 Apr; 36(12):1199-1206. PubMed ID: 29373100
[TBL] [Abstract][Full Text] [Related]
72. Neoadjuvant alectinib in locally advanced lung adenocarcinoma with anaplastic lymphoma kinase rearrangement: case series and literature review.
Wang Z; Wu R; Li C; Cheng K; Di Y; Lv T; Liu H; Song Y
Anticancer Drugs; 2023 Nov; 34(10):1069-1075. PubMed ID: 36688904
[TBL] [Abstract][Full Text] [Related]
73. Distribution and therapeutic outcomes of intergenic sequence-ALK fusion and coexisting ALK fusions in lung adenocarcinoma patients.
Cai C; Tang Y; Li Y; Chen Y; Tian P; Wang Y; Gong Y; Peng F; Zhang Y; Yu M; Wang K; Zhu J; Lu Y; Huang M
Lung Cancer; 2021 Feb; 152():104-108. PubMed ID: 33444901
[TBL] [Abstract][Full Text] [Related]
74. BRAF V600E mutation as a novel mechanism of acquired resistance to ALK inhibition in ALK-rearranged lung adenocarcinoma: A case report.
Sui A; Song H; Li Y; Guo L; Wang K; Yuan M; Chen R
Medicine (Baltimore); 2021 Feb; 100(8):e24917. PubMed ID: 33663128
[TBL] [Abstract][Full Text] [Related]
75. Lung adenocarcinoma with a novel SRBD1-ALK Fusion responding to crizotinib.
Chen Y; Zhang X; Jiang Q; Wang B; Wang Y; Junrong Y
Lung Cancer; 2020 Aug; 146():370-372. PubMed ID: 32527613
[TBL] [Abstract][Full Text] [Related]
76. Optimal management of ALK-positive NSCLC progressing on crizotinib.
Metro G; Tazza M; Matocci R; Chiari R; Crinò L
Lung Cancer; 2017 Apr; 106():58-66. PubMed ID: 28285695
[TBL] [Abstract][Full Text] [Related]
77. A Case of Lung Adenocarcinoma Response to Alectinib Harboring a Rare EML4-ALK Variant, Exon 6 of EML4 Fused to Exon 18 of ALK.
Liu L; Hou F; Liu Y; Li W; Zhang H
J Natl Compr Canc Netw; 2021 Nov; 20(1):2-6. PubMed ID: 34763318
[TBL] [Abstract][Full Text] [Related]
78. Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants.
Cha YJ; Kim HR; Shim HS
J Transl Med; 2016 Oct; 14(1):296. PubMed ID: 27756333
[TBL] [Abstract][Full Text] [Related]
79. Fibroblast growth factor receptor 3 overexpression mediates ALK inhibitor resistance in ALK-rearranged non-small cell lung cancer.
Sakashita T; Yanagitani N; Koike S; Low SK; Takagi S; Baba S; Takeuchi K; Nishio M; Fujita N; Katayama R
Cancer Sci; 2022 Nov; 113(11):3888-3900. PubMed ID: 35950895
[TBL] [Abstract][Full Text] [Related]
80. Real-World Treatment Sequencing, Toxicities, Health Utilities, and Survival Outcomes in Patients with Advanced ALK-Rearranged Non-Small-Cell Lung Cancer.
Schmid S; Cheng S; Chotai S; Garcia M; Zhan L; Hueniken K; Balaratnam K; Khan K; Patel D; Grant B; Raptis R; Brown MC; Xu W; Moriarty P; Shepherd FA; Sacher AG; Leighl NB; Bradbury PA; Liu G
Clin Lung Cancer; 2023 Jan; 24(1):40-50. PubMed ID: 36270866
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
